Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I clinical trial to test the safety and tolerability of intravitreal
ranibizumab in the treatment of radiation retinopathy following plaque brachytherapy for
patients with choroidal melanoma using the incidence and severity of events criteria.
The secondary objective is to assess the efficacy of intravitreal ranibizumab on regression
of radiation retinopathy by ophthalmic examination, fundus photography, fluorescein
angiography, and optical coherence tomography, as well as visual acuity.